December 13, 2013 -
According to Aventyn, Vitalbeat is designed to help clinicians better manage chronic disease patient populations, including congestive heart failure patients and to prevent avoidable readmissions.
Vital Connect’s HealthPatch MD biosensor is capable of capturing clinical-grade biometric measurements in a continuous, configurable and non-obtrusive manner using a patch worn on the chest. According to the company, thissensor enables clinical-grade measurements of health metrics including ECG, heart rate, heart rate variability, respiratory rate, skin temperature, and others.
“Vital Connect is pleased to be partnering with Aventyn due to their significant experience in remote patient monitoring in North America, Europe and Asia,” Vital Connect CEO, Nersi Nazari said. “The collaboration between Aventyn and Vital Connect will be a driving force to advance the deployment of mobile patient monitoring technologies in hospitals and other care facilities. Not only will the Vitalbeat platform and HealthPatch MD biosensor improve quality of care, it will also help hospitals reduce overhead by decreasing the number of readmissions after a procedure because doctors will be able to detect complications and take action much sooner.”
According to a recently published research report, the global healthcare biometrics market is set to reach $5.9 billion by 2019, growing at a CAGR of 25.9%. Growing security concerns with healthcare facilities and medical insurance have so far driven the growth of this market.
“We are delighted to collaborate with Vital Connect, a clear innovator in wearable clinical grade biosensors that improve personalized health monitoring,” Navin Govind, founder and CEO at Aventyn said. “The combination of the HealthPatch MD biosensor with Vitalbeat will enable our clinicians and innovative hospital partners to deliver revolutionary standard-of-care and cost-effective treatment that improve outcomes to meet the global need for heart failure care. The Vital Connect medical technology leadership and Aventyn mobile disease monitoring solution infrastructure with smart analytics can now scale to deliver affordable care to chronic patients and treat millions of discharge populations regardless of location.”